The latter, working through inhibiting the activation of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1), T cell membrane proteins suppressing immune response, have shown unprecedented anti-tumor response in clinical trials [6,7], but only in a subgroup of patients. This evidence concerns the gene PDCD1 and neoplasm.